The earnings call highlighted significant advancements in Alector's clinical trials and collaborations, particularly with GSK, for developing treatments for neurodegenerative diseases. However, challenges remain in addressing the unmet needs in frontotemporal dementia and navigating complex regulatory requirements.

Company Guidance -

Q3 2025

During Alector's earnings call for the second quarter of 2025, the company provided guidance on its ongoing and future clinical programs. The call highlighted the anticipated release of top-line data from their pivotal Phase III INFRONT-3 trial of latozinemab by mid-fourth quarter 2025. This trial targets frontotemporal dementia (FTD) due to the GRN gene mutation, with a focus on elevating progranulin levels. Alector plans to submit a Biologics License Application (BLA) and Marketing Authorization Application (MAA) in 2026, collaborating with GSK on commercialization strategies. The company also updated its financial guidance, forecasting collaboration revenue between $13 million and $18 million for 2025, with research and development expenses estimated at $130 million to $140 million, and general and administrative costs projected at $55 million to $65 million. Additionally, Alector discussed its Phase II trial of AL101 for early Alzheimer's disease, expected to conclude in 2026, and emphasized its proprietary technology platform for delivering therapies across the blood-brain barrier, including programs targeting Alzheimer's and Parkinson's diseases.

Promising Phase III Trial for Latozinemab

Alector's Phase III INFRONT-3 trial for latozinemab is expected to deliver top-line data by mid-fourth quarter 2025. The trial focuses on treating frontotemporal dementia due to the GRN gene mutation, a rare condition with no current approved therapies.

Partnership with GSK

Alector is advancing launch readiness activities for latozinemab in collaboration with GSK, indicating strong support and resources for potential commercialization.

Multiple Late-Stage Clinical Programs

Alector is advancing a Phase II trial for AL101, targeting early Alzheimer's disease. This antibody shares a similar mechanism with latozinemab but is suitable for more prevalent neurodegenerative diseases.

Robust Financial Position

Alector closed the quarter with $307.3 million in cash, expected to provide runway into the second half of 2027, enabling continued investment in clinical and preclinical programs.

Alector (ALEC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALEC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.41 / -	-0.43	―	―	―
Aug 07, 2025	2025 (Q2)	-0.46 / -0.30	-0.4	25.00% (+0.10)	―
May 08, 2025	2025 (Q1)	-0.48 / -0.41	-0.38	-7.89% (-0.03)	―	―
Feb 26, 2025	2024 (Q4)	-0.62 / -0.02	-0.49	95.92% (+0.47)	―
Nov 06, 2024	2024 (Q3)	-0.53 / -0.43	-0.53	18.87% (+0.10)	―	―
Aug 07, 2024	2024 (Q2)	-0.50 / -0.40	0.02	-2100.00% (-0.42)	―
May 08, 2024	2024 (Q1)	-0.51 / -0.38	-0.55	30.91% (+0.17)	―	―
Feb 27, 2024	2023 (Q4)	-0.77 / -0.49	-0.63	22.22% (+0.14)
Nov 07, 2023	2023 (Q3)	-0.66 / -0.53	-0.56	5.36% (+0.03)	―	―
Aug 03, 2023	2023 (Q2)	-0.81 / 0.02	0.12	-83.33% (-0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALEC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$1.46	$2.15	+47.26%
May 08, 2025	$1.04	$1.17	+12.50%
Feb 26, 2025	$1.72	$1.66	-3.49%
Nov 06, 2024	$5.24	$5.64	+7.63%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alector Inc (ALEC) report earnings?

Alector Inc (ALEC) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Alector Inc (ALEC) earnings time?

Alector Inc (ALEC) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALEC EPS forecast?

ALEC EPS forecast for the fiscal quarter 2025 (Q3) is -0.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing